Invention Grant
US08114398B2 EGLN2 variants and use thereof in preventing or treating thromboembolic disorders and coronary heart disease
失效
EGLN2变体及其在预防或治疗血栓栓塞性疾病和冠心病中的用途
- Patent Title: EGLN2 variants and use thereof in preventing or treating thromboembolic disorders and coronary heart disease
- Patent Title (中): EGLN2变体及其在预防或治疗血栓栓塞性疾病和冠心病中的用途
-
Application No.: US12089627Application Date: 2006-09-30
-
Publication No.: US08114398B2Publication Date: 2012-02-14
- Inventor: Detlef Kozian , Matthias Herrmann
- Applicant: Detlef Kozian , Matthias Herrmann
- Applicant Address: FR Paris
- Assignee: Sanofi-Aventis
- Current Assignee: Sanofi-Aventis
- Current Assignee Address: FR Paris
- Agent J. Darrell Fontenot
- Priority: DE102005048898 20051012
- International Application: PCT/EP2006/009518 WO 20060930
- International Announcement: WO2007/042166 WO 20070419
- Main IPC: A61K38/46
- IPC: A61K38/46 ; C12N15/00 ; C12N9/14 ; C12N15/11
Abstract:
The present invention refers to human EGLN2 variants having at position 58 of the amino acid sequence a serine or a leucine and their use in the prevention or treatment of thromboembolic or coronary heart diseases, in particular stroke, prolonged reversible ischemic neurological deficit (PRIND), transitoric ischemic attack (TIA), myocardial infarction and/or early myocardial infarction.
Public/Granted literature
Information query
IPC分类:
